GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

Orchard Therapeutics, a UK-based gene therapy developer which counts pharmaceutical firm GlaxoSmithKline (GSK) as its second largest investor, floated in the US yesterday in a $200m initial public offering.

The IPO consisted of almost 14.3 million American depositary shares (ADSs), each representing a single ordinary share, issued on the Nasdaq Global Select Market and priced at $14.00 each. It had set a $14 to $16 range for 13.3 million ADSs last week.

Founded in 2015, Orchard is working on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn